Based on this, antiangiogenic therapy combined with immunotherapy (programmed death ligand 1 [PD-L1] inhibitor) and chemotherapy has been approved by the FDA as first-line treatment for advanced NSCLC patients. Here, CD274 is linked to non-small cell lung carcinoma.